Selected article for: "acute ards respiratory distress syndrome and lung field"

Author: Muñoz-Jiménez, Alejandro; Rubio-Romero, Esteban; Fuente, José Luis Marenco de la
Title: Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19()
  • Cord-id: iw5rb420
  • Document date: 2021_4_12
  • ID: iw5rb420
    Snippet: The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infectio
    Document: The outcome of the SARS-CoV-2 (COVID-19) infection fundamentally affects the lung field, causing ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS). This process is an inflammatory picture, involving an NLRP3 INFLAMOSOME-triggered cytokine storm, the main player in alveolar destruction. IL-1 beta stands out among the cytokines that are triggered in this picture. ANAKINRA is a potent biological drug, capable of blocking this IL 1 beta. We propose its use in controlling ARDS secondary to COVID-19 infection.

    Search related documents:
    Co phrase search for related documents